For security purposes
FOR SECURITY PURPOSES - because Internet Explorer is no longer supported by Microsoft, we suggest that you interact with our secure site through one of our supported browsers - Google Chrome, Firefox, or MS Edge. If you continue to use this website with Internet Explorer you do so at your own risk and you may encounter problems.

Phenomenex Presents BioPharma Innovation Symposium

First-ever virtual symposium to offer insights from key industry thought leaders.

Torrance, CA— Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, is hosting their first-ever virtual biopharma symposium. The symposium is covering important topics related to key considerations when developing robust analytical methods for biotherapeutics with key industry thought leaders from institutions and companies such as MIT, Avid Bioservices, and Versatope Therapeutics.

The theme of this year’s symposium is "Analytical Considerations When Measuring Biotherapeutic Critical Quality Attributes (CQAs)" and focuses on how analytical consumables play an impactful role in generating quality data used to make critical drug development decisions. “We are truly excited because this event is one of many to foster conversations and align partnerships among top thought leaders and the broader biotherapeutic drug development community,” said Tran Pham, Phenomenex Global Market Development Manager for Biopharma. Dr. John Gebler, Director of Strategic Biopharma Business for Phenomenex said, “This is a prestigious event that will provide a platform for in-depth discussions, knowledge sharing, and collaboration on the latest advancement, challenges, and opportunities in the field of biopharmaceuticals."

Featured sessions include:

  • Revisiting the Central Dogma in the Age of the Epigenome & Epitranscriptome
    Dr. Peter Dedon, M.D., Ph.D., Singapore Professor of Biological Engineering, Massachusetts Institute of Technology Lead PI, Singapore-MIT Alliance for Research & Technology Antimicrobial Drug Resistance IRG
  • A Rapid Method with Wide Dynamic Range to Assess Size-Based Purity and Concentration of AAV5 Particles by SEC
    Kilian Witzel, Sr. Scientist at Avid Bioservices
  • The Challenges & Opportunities for the Future of Therapeutics & Vaccines
    Dr. Chris Locher, Ph. D, Chief Executive Officer at Versatope Therapeutics

To learn more and register for the event: https://bit.ly/3suk9Fa

About Phenomenex
Phenomenex is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in industrial, clinical research, government, and academic laboratories. From drug discovery and pharmaceutical development to food safety and environmental analysis, Phenomenex chromatography solutions accelerate science and help researchers improve global health and well-being. For more information, please visit www.phenomenex.com and follow the company's blog at www.scienceunfiltered.com

Let’s connect: LinkedIn, Twitter, Facebook, Instagram and YouTube

Contact Information: Jannette Avila, Senior Manager - Brand and Public Relations
jannettea@phenomenex.com / M: +1 (310) 212-0555

biopharma